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Assessment of Tolerability of β- blockade therapy in Patient with Left 
Ventricular Systolic Dysfunction Heart Failure 




Back ground: Little data exist to demonstrate the tolerability of β-blocker therapy in an unselected 
community heart failure population already treated with the clinical trial or higher dose ACEI or 
ARB. 
Methods and results: 141 patients who had left ventricular systolic failure on standard therapy 
were recruited in our study. Patients were assigned to receive either Carvedilol or Bisoprolol.  
Conclusion: This prospective observational study showed that β-blocker therapy is well tolerated 
and can be safely titrated in an out-patient setting. 
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eart failure, a complex clinical 
syndrome that develops as a 
consequence of cardiac disease is an 
increasingly common condition. The 
prevalence of heart failure in a recent 
community based study was 3.9% in people 
aged over 55 years old1. The prevalence 
increased with age to between 11-13% in 
those over 75 years old. Based on such 
figures, one would expect prevalence in 
Ireland of approximately 80.000 people. Heart 
failure remains a lethal condition. The most 
recent figures (which admittedly do not reflect 
recent advances) suggest a five year survival 
rates of less than 40% from the time of 
diagnosis2. It is a condition which represents 
the number one public health problem in 
cardiovascular medicine and this is reflected 
in public spending. In 1991 the US spending 
on heart failure represented 4.8% of the total 
Medicare budget3.
The frequency of hospitalization accounts for 
much of the   economic burden in the 
condition. It is a condition that is associated 
with readmission rates of 20%-40% especially 
within three month of discharge4.
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Many advances have been made in the 




To assess and  compare tolerability of a 
conventional β-blocker (Bisoprolol) with 
Carvedilol (which has an additional α
blocking activity)  in an unselected group of 
patients with  LV systolic dysfunction  on 
maximal medical treatment  with RAAS 
modifying therapy (either ACEI or ARB ) 
attending a specialist heart failure clinic.                                                                         
Method 
 This prospective observational study 
recruited patients referred from either the 
heart failure service or from cardiology OPD 
at St- Vincent’s university hospital Dublin, 
Ireland from October 2004 to September 
2005. 
 Each patient was initially screened by the 
investigator following admission or referral 
including review their echocardiography 
study. The heart failure service reviews all 
patients admitted through Accident and 
Emergency with a diagnosis of heart failure.                     
Initially Carvedilol was added to the 
patients’ drug therapy as Bisoprolol tablets 
1.25mg were not available at that time.  
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Subsequent to Bisoprolol 1.25mg becoming 
available on the market patients were 
alternately assigned to either Bisoprolol or 
Carvedilol. Seventy-nine patients received 
Carvedilol and 62 received Bisoprolol.                                                                                
 The dose of β-blocker was up-titrated at 
two weeks intervals according to the current 
consensus recommendations (table1). Prior to 
this the investigator examined all patients to 




Carvedilol Bisoprolol titration 
3.125 mg BD 1.25 mg ODStep1 
6.25 mg BD 2.5 mg OD Step2 
12.5 mg BD 3.75 mg ODStep3 
25 mg BD 5 mg OD Step4 
50 mg BD 7.5 mg OD Step5 
10 mg OD Step6 
During each visit the patients had their blood 
pressure and pulse monitored every 30 
minutes for two hours after the dose was up-
titrated.            
The target dose of Bisoprolol was > 5 mg 
once daily. The target dose of Carvedilol was 
25mg twice daily and the maximum dose 




 One hundred and forty one patients with left 
ventricular systolic dysfunction heart failure 
had β-blockers added to their standard 
therapy. 
 
Inclusion criteria  
Signs and symptoms of heart failure with 
echocardiographic and Doppler evidence of 
left ventricular systolic dysfunction (ejection 
farction less than 45 %) 
 
Exclusion criteria  
Patients excluded were those with  history of 
asthma confirmed by significant reversible 
obstructive airways disease on pulmonary test 
, and those with  high degree of AV block (2nd 
and 3rd Degree Heart Block) , sinus nodal 
disease and chronotropic incompetence , 
unless paced . 
Patient characteristics  
The demographic and baseline characteristics 
of the total patient population are presented in 
Table 2 and 3. 
 All patients were on maximally tolerated 
ACE inhibitor or ARB before initiation of β-
blocker therapy (fig2) Approximately 51% of 
patients were on target dose ACE inhibitor / 
ARB ( perindopril ≥4 mg , ramipril ≥ 5 mg bd 
, innovace ≥ 10 mg bd , lisinopril ≥ 20 mg od 
, losartan ≥ 50 mg od , candesartan ≥ 8 mg   
od ) . All were on loop diuretics , 37.6% were 
on digoxin , 38.3% were on nitrates and 6.4% 
were on spironolactone at initiation of β-
blocker titration ( all p = NS for C versus TD , 
where C is the group of patients who tolerate 
small dose of β-blocker therapy or are deemed 
intolerant and TD is the group who achieve 
target dose ).  12 % of the patients in this 
study had started β-blocker therapy during 
admission with heart failure (NYHAIV)      
fig (1).                                              
 
Fig(1): shows The symptomatic Classification 
of Heart Failure during initiation b-blocker 
therapy. 
 
Fig (2): Shows the percentage of patients on 
different doses of ACE inhibitors and ARB. 
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Table 2 : Demographic characteristics between Bisoprolol and Carvedilol group.   
 
Characteristic                              Total Population         Bisoprolol           Carvedilol             P (BVC)   
N 141 62 79  
Age± SD (years )                                   67.98±11.43          68.53±12.03     67.54±10.99      P=0.60 
Male (n): female (n)                              98:43                     44 : 18               54:25                 p=0.738 
ACE/ARB:Neither: ACE:ARB:Both   3:122:12:4             1:56:2:3              2:66:10:1          p=0.051 
Target dose ACEi/ARB,yes                  74:64:3                  35:26:1               38:29:2             p=0.431 
(n): no (n): neither 
Nitrate , yes (n):no(n)                             54:87                    29:33                  25 :54                p=0.067 
Loop diuretic dose ***±SD(mg)          50.25± 28.39         52.36(34.1)        48.44(22.48)      p=0468 
Digoxin,yes (n):no(n)                           53:88                     21:41                  32:47                  p=0.419 
Aldactone, yes (n): no(n)                      9:132                     4:58                    5:74                   p=0.693 
Mean SBP/DBP before titration±        127/74±20/13         125/74±22/13   127/74±19/13     p=0.516 
SD(mmHg)(between groups)                                                                                                   p=0.989 
Mean SBP before titration ±SD       121/70±21/13       121/71±21/12   121/70±21/13           p=0.67 
SBP after titration ±SD(mmHg)                                                                                               p=0.028 
(within groups) 
DBP before titration±SD/DBP             74±13:70±13        74±13:71±12     74±13:70±13      p=0.001 
After titration ±SD(mmHg)(within                                                                                          p=0.005 
Groups) 
Mean urea pre titration (SD)                 8.24±3.64             8.04(3.7)            8.32 (3.6)           p=0.666 
(between groups) 
Mean urea post titration (SD)               8.55±4.03              8.34(4.0)            8.63 (4.0)           p=0.667 
( between groups ) 
Mean urea pre (SD):mean urea             8.19(3.6):8.5        8.04(3.7)             8.32(3.6)            p=0.221 
Post titration (SD) (within groups)       (4.0)                      8.34 (4.0)            8.62 (4.0)          p=0.370 
Sinus rhythm, yes (n) :no(n)                 47:94                     17:45                   30:49                p=0.187 
 
Follow up  
Duration of follow up was one year, with the 
investigator reviewing all patients at three and 
six months post completion of β-blocker 
titration. 
 
Statistical Analysis  
 Age , loop diuretic dose , mean systolic and 
diastolic blood pressure both before and after 
titration , mean urea pre and post titration 
were all compared using the Student t-Test 
with a p< 0.05 demonstrating a significant 
difference . 
 Proportion of male to females in the study 
population of ACE inhibitor to ARB dose, 
whether nitrates, digoxin , spironolactone  
 
were administered or not , whether patients 
were in sinus rhythm , hypertensive or had 
underlying ischemia were all compared using 
Chi-squared test . Significance was attributed 
to p value < 0.05. 
 
Although the sample population is small (n= 
141), the group was very representative of a 
typical heart failure population, given the fact 
that patients form hospital admissions, GP 
referrals etc were included in the study. Allied 
to this is the fact that the only exclusion 
criteria were patients in whom beta-block 
would be contra-indicated, and those with 
high degree AV block. 
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Table 3: Baseline characteristics of total population and patient group who achieved target dose β-
blocker therapy (TD) or not (C).   
 
Characteristic                                 Total Population        C Group              TD Group        P (TD V C)  
N 141 47 94
Age± SD (years )                              67.98±11.43            72.81±10.05        65.56±11.36        P=0.00 
Male (n): female (n)                         98:43                        26 : 21                 72:22                   p=0.01 
ACE/ARB:Neither(n): ACE(n)        3:122:12:4                2:38:5:2              1:84:7:2               p=0.521 
 ARB(n):Both (n)  
Target dose ACEi/ARB,yes             74:64:3                     25:20:2                49:44:1                p=0.752 
(n):no (n): neither(n) 
Β-Blocker type ,BS(n):CV(n)          62:79                        27:20                   35:59                   p=0.023 
Nitrate, yes(n): no(n)                       54:87                         21:26                   33:61                   p=0.270  
Loop diuretic dose ***±SD(mg)     50.25± 28.39             47.62±28.27       51.69±28.54        p=0.457 
Digoxin,yes (n):no(n)                      53:88                         15:32                   38:56                  p=0.325 
Aldactone, yes (n): no(n)                 9:132                         2:45                     7:87                    p=0.465 
SBP/DBP before titration ±SD        127/74±20/13       123/70±21/12**   128/75±19/13**    p=0.128 
 P=0.020  
SBP/DBP after titration ±SD          121/70±21/13        118/69±23/13       123/71±20/13        p=0.270 
 P=0. 335        
Mean urea pre titration(SD)            8.24±3.64                   9.61±4.54             7.48±2.8           p=0.001 
Mean urea post titration(SD)           8.55±4.03                   10.52±5.17           7.53±2.88         p=0.001 
Sinus rhythm, yes (n) :no(n)            47:94                          15:32                    32:62                p=0.801 
Ischaemia, yes (n):no(n)                  99:42                          37:10                     62:32               p=0.118 
Hypertension ,yes (n) : no(n)           30:111                        11:36                     19:75               p=0.662 




β-blockers titration was carried out in 141 
consecutive patients with left ventricular 
systolic dysfunction. Ninety-four (67%) 
achieved target dose (TD) β-blocker therapy.  
Of the remaining 47 patient, 24 achieved low 
dose β-blocker therapy and 23 were deemed 
intolerant           (Table 2, 3).                 
 Age and gender differences were noted 
between the groups with a higher proportion 
of males in the C group. The mean urea 
values were significantly higher in patients in 
the C before and titration. There is no 
statistically significant drop in systolic blood 
pressure (SBP) between the groups before or 
after titration but there were significant drops 
in it SBP within the groups before and after 
titration. However, diastolic blood pressure  
 
(DBP) levels were significantly higher pre-
titration for the TD group and dropped 
significantly during titration to the level of the 
C group. The DBP levels did not drop in the 
C group after titration.  
 
Dosage and Tolerability 
118 patients (83.7%) tolerated β-blocker 
during one years of follow up (Fig 3). 
Fig3: Tolerance of β-blocker 
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Table 4: type of beta blocker * tolerability of blockers cross tabulation 
 
Total  
tolerability of beta    blockers Type of beta    blocker 
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74.7% of patients tolerated target dose of 
Carvedilol. 12.7% tolerated small doses of 
Carvedilol (≤ 6.25 mg twice daily). This makes 
total tolerability of Carvedilol 87.4%. However 
only 56.5% tolerated target dose of Bisoprolol and 
22.6% tolerated low doses of Bisoprolol (≤ 2.5 mg 
once daily) making the total tolerability of 
Bisoprolol 79.1% (Fig 4. Table 4). 
 
Fig (4): Shows tolerability of different doses 
of carvedilol and bisoprolol:  
 
16.3% of patient (n-23) were unable to 
tolerate β-blocker therapy, (n-10) in 
Carvedilol group and( n-13) in Bisoprolol 
group (Table 5).             
 
Five of the patients were intolerant to β-
blocker because of worsening heart failure 
(n=5), objectively confirmed by weight gain 
and chest x-ray, and subjectively by 
exacerbation of symptoms (dyspnoea, fluid 
retention and quality of life questionnaire).    
 
Seven of the patients were deemed 
intolerant because of symptomatic 
hypotension confirmed by blood pressure 
monitor for four hours. (Systolic blood 
pressure less than 90 mmHg).               
 
Six patients declined to continue β-blocker 
titration. Five patients were intolerant of β-
blocker because of syncope, bradycardia less 
than40, as per ECG, worsening respiratory 
status, Reynaud's phenomenon, pemphigus 
(each 1 patient).                                                  
 
Fig (5): Shows reasons for β -blockers 
intolerability. 
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Table 5 (below). Shows adverse event rates compared to USCP and CIBIS II  
 
Present study CIBS II USCP  
Bisoprolol Carvedilol Bisoprolol PlaceboCarvedilol PlaceboEvent 




16.3% of patient who did not tolerate the β-
blocker, crossed over to the other one. 
 There was a small percentage, which were 
able to tolerate the alternative.  
 23.3% required adjustment of concomitant 
medication to achieve β-blocker titration. 
51% developed systolic blood pressure of less 
than 90 during up-titration. 87% of those were 




There is considerable data from the 
meta–analyses of many small trials and from 
CIBISII showed the beneficial role of β-
blocker therapy in heart failure5-7 .The 
modern era of large randomised controlled 
trials involving β-blockers really started with 
the US Carvedilol Heart Failure Study, in 
which a very substantial reduction in 
mortality and morbidity was shown with 
Carvedilol.  Another study with Carvedilol 
was the smaller Australia- New Zealand Heart 
Failure Research Group Trial of around 300 
patients following myocardial infarction8.
This showed a reduction in a composite end 
point of hospitalizations but focused on one 
aspect –the effect on left ventricular 
function—which suggested that it was 
improved by Carvedilol. This effect has now 
become an important future of β-blocker 
treatment.  The Copernicus Trial showed the 
safety and efficacy of β-blocker therapy in 
sever heart failure. The follow-up of our study 
was one year which was equal to MERIT HF, 
was shorter than CIBIS II and longer than 
COPERNICUS and USCP. The mean LVEF 
of 29.4%, is comparable to those on CIBIS II, 
MERIT-HF and is higher than those in 
Copernicus and USCP. A mean age of 67 
years make this study's population older 
compared to the previous mentioned trial. The 
number of male patients was double the 
number of female. This is consistent with 
previous trials (female gender under-
represented). It seems quite clear from the 
totality of the data presented that β-blockers 
substantially reduce mortality and morbidity 
in patients with NYHA class II-IV CHF 
caused by left ventricular systolic of all 
causes9-11 . These large trials are supported by 
meta-analyses of smaller studies 12,13.
The findings from this study were 
consistent with previous trials, which showed 
large populations tolerating high dose 
Carvedilol better than Bisoprolol, but at a low 
dose the tolerability is comparable (Fig.4). 
 Clinical trials have shown that the 
maximum dose of β-blockers was determined 
not by their clinical response but by a pre 
specified target dose. Although target doses 
were successfully achieved by many patients 
and produced significant clinical benefits, 
most trials did not evaluate whether lower 
doses would be effective, lower doses were 
prescribed only if target dose was not 
tolerated. Only one trial (with Carvedilol) has 
compared the clinical effects of different 
doses of  β-blockers. Although high dose of 
Carvedilol (25 mg twice daily) appeared to be 
more effective than low doses (6.25 mg twice 
daily) in that study; low doses were associated 
with significant improvement in ejection 
fraction, and significant decrease in  the risk 
of death or hospitalization14. Therefore, an 
effort should be made to achieve target doses, 
low doses β-blockers should be maintained if 
high doses are not tolerated. Nevertheless, the 
α blocking vasodilatory activity of Carvedilol 
may make early upward dose titration of this 
drug better tolerated than β-adrenergic 
antagonism without vasodilatory activity. It 
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was observed that patient on Carvedilol 
tended to have more dizziness (13-15%), most 
probably due to its α-blocker effect. 
12% of our patients had started β-blockers 
therapy during admission with heart failure 
(NYHA Class IV) and they tolerated this 
well. 
 In a setting of worsening heart failure 
during β-blockers therapy, β-blockers dose 
should not be up titrated further and if 
necessary can be decreased gradually. Abrupt 
withdrawal of treatment with β-blockers can 
lead to dramatic clinical deterioration and 
should be avoided. 
 
The ideal β-blockers choice in chronic 
heart failure. 
 β-blockers achieve most of these effects by 
blocking the deleterious effect of chronic over 
exposure of the heart to noradrenaline  which 
cause cardiac hypertrophy, ischaemia and 
myocyte damage. When selecting  β-blockers, 
no clear consensus exists as yet on which of 
the pharmacological activities of β-adrenergic 
antagonists are necessary or desirable in 
treatment of heart failure, however, it is 
probably advisable to choose a β1 selective 
drug because that improves tolerability. It 
would also seem prudent to select one that is 
lipophilic, this particular point is debatable. 
However, it is noteworthy that  most existing 
data linking β-blockers with reductions in 
sudden death are for more or less lipophilic 
drugs – propranolol , Timolol , Metoprolol , 
bisoprolol- . Nadolol , atenolol ,and sotalol , 
which are not lipophilic , have not had the 
same impact on sudden death post myocardial 
infarction . This is not to suggest that the 
latter drugs do not act via β-blockers, or that 
they do not reduce blood pressure and infarct 
rates. They simply have not had the same 
impact on sudden death as the lipophilic β-
blockers.  β-blockers- like Carvedilol- which 
are β1,2 and α blockers can interfere with the 
adverse effect of sympathetic activation 
through several noradrenergic mechanisms 
which is important in severe heart failure , 
they also have anti-oxidant and anti-
endothelin properties . However, β-blockers 
with significant ISA properties are shown to 
have excess mortality in patients taking active 
drug and the trial was terminated early 
(xamaterol in severe heart failure study ) 15.
Both Carvedilol and Metoprolol are highly 
lipophilic compounds and are metabolized 
and cleared by the liver. In the setting of 
hepatic congestion, dosage reduction may be 
required. Bisoprolol is less lipophilic and 
exhibits both hepatic and renal clearance. 
There does not appear to be any significant 
interaction with other cardiac drugs. 
 
Conclusion  
This prospective observational study showed 
high tolerability levels (83.7%) in an 
unselected community based heart failure 
population. Carvedilol is better tolerated than 
Bisoprolol at high dose, partly due to α
blocking vasodilatory effect, which reduces 
after load and offsets to some degree the early 
negative inotropic effect of β-blockers and 
potentially improve tolerability and early 
upward dose titration. However at low doses 
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